Our clients are actively seeking oversea investment and acquisition opportunities in medical devices that have promising market in China. Join our partnering forum during JPM week and meet potential investors and partners for the emerging China market.
If you are interested in meeting one of the following Chinese companies or VCs, please submit your company deck for consideration here. Selected companies will get an chance to pitch in front of these investors during our “Pitch to investor” session. Registration is required. There is no additional cost to participate the “Pitch to investor” session. Please contact Ginger.Ding@Mybiogate.com for any questions.
Fosun Pharma: Top1 oversea dealmaker in China. As one of the earliest companies that work on in vitro diagnostics (IVD) in China, Fosun’ products cover clinical chemistry, clinical immunology, molecular diagnostics (including DNA microarray), clinical microbiology and other laboratory medicine fields. These are currently leading products in the field of medical diagnosis in China. Fosun is a service provider in China and a participant in the international market.
Weigao Group: Weigao principally engaged in the research and development, production and sale of single-use medical devices. The Group has a wide range of products, which includes: i) consumables (infusion sets, syringes, medical needles, blood bags, pre-filled syringes, blood sampling products, and other consumables); ii) orthopedic materials and iii) blood purification consumables and equipment. The Group has extensive sales network comprising 25 sales offices, 38 customer liaison centers and 170 municipal representative offices, as well as a total customer base of 5,159 (including 3,090 hospitals, 414 blood stations, 611 other medical units and 1,044 distributors).
MicroPort Scientific Corporation: With over 300 products currently approved for use in over 8,000 hospitals worldwide, MicroPort® have devoted themselves to this mission of advancing the forefront of technology innovation to develop the best and most affordable medical therapies to treat patients around the globe.
Cowin Venture: Cowin venture is an early-stage focused venture based in China, with both RMB and USD funds totaling over $400M under management. The US fund is only for healthcare, the portfolio includes diagnostics, pharmaceuticals, medical device.
Lumira Ventures: Lumira Capital leverages over 25 years of experience as one of North America’s leading health care and life sciences venture capital investors. The firm invests in biopharmaceutical, medical device, health IT and consumer health companies whose products deliver transformative improvements in the lives of patients worldwide.
We will host an upcoming China Focus@JPM week on Jan. 6th 2019. Do not miss the chance meeting the large body of buyers at one place and explore potential partnership possibilities.